2019 News

List of articles in category 2019 News
Title Date
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 13 December 2019
Marinus Pharmaceuticals Announces Closing of $70 Million Public Offering of Common Stock and Concurrent Private Placement Including Full Exercise of Underwriters’ Option to Purchase Additional Shares 13 December 2019
Marinus Pharmaceuticals Appoints Elan Ezickson to Board of Directors 12 December 2019
Corrected Press Release: Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement 11 December 2019
Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement 11 December 2019
Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Concurrent Private Placement 10 December 2019
Marinus Announces Ganaxolone Orphan Epilepsy Program Updates Including Planned Clinical Program in Tuberous Sclerosis Complex 09 December 2019
Marinus Presents Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus at the American Epilepsy Society Annual Meeting 06 December 2019
Marinus Pharmaceuticals Announces Presentations on Ganaxolone at AES Annual Meeting 27 November 2019
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 08 November 2019
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter Financial Results 06 November 2019
Marinus Pharmaceuticals Appoints Joe Hulihan, M.D., as Chief Medical Officer 29 October 2019
Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society Meeting 17 October 2019
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 27 September 2019
Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial 26 September 2019
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 23 August 2019
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial Results 08 August 2019
Marinus Pharmaceuticals Announces Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum Depression 23 July 2019
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) 19 June 2019
Marinus Pharmaceuticals to Participate at Upcoming Investor Conferences 03 June 2019
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results 01 May 2019
Marinus Pharmaceuticals Provides Business Update and 2018 Financial Results 11 March 2019
Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy 06 March 2019
Marinus Pharmaceuticals to Present at the Cowen Healthcare Conference 05 March 2019
Marinus Announces Leadership Transition 26 February 2019
Marinus Pharmaceuticals to Present at the Leerink Healthcare Conference 20 February 2019
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 05 February 2019
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 25 January 2019